The affective dimension of pain as a risk factor for drug and alcohol addiction

Alcohol

Volumn 49, Issue 8, 2015, Pages 803-809

  LeBlanc, Dana M ^a   McGinn, M Adrienne ^a   Itoga, Christy A ^a   Edwards, Scott ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Amygdala; Corticotropin releasing factor; Nucleus accumbens; Pain; Prefrontal cortex

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; DYNORPHIN; NEUROPEPTIDE;

AFFECT; ALCOHOLISM; ANXIETY; ARTICLE; CENTRAL NUCLEUS (AMYGDALA); CHRONIC PAIN; COMORBIDITY; HEROIN DEPENDENCE; HUMAN; NOCICEPTION; NONHUMAN; NUCLEUS ACCUMBENS; POPULATION RISK; PREFRONTAL CORTEX; REWARD; RISK FACTOR; SENSITIZATION; SIGNAL TRANSDUCTION; AMYGDALA; ANIMAL; BRAIN; HYPERALGESIA; METABOLISM; MOOD DISORDERS; PAIN; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS;

AFFECT; ALCOHOLISM; AMYGDALA; ANIMALS; BRAIN; CHRONIC PAIN; CORTICOTROPIN-RELEASING HORMONE; DYNORPHINS; HUMANS; HYPERALGESIA; MOOD DISORDERS; NEUROPEPTIDES; NUCLEUS ACCUMBENS; PAIN; PREFRONTAL CORTEX; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 84983130306     PISSN: 07418329     EISSN: 18736823     Source Type: Journal    
DOI: 10.1016/j.alcohol.2015.04.005     Document Type: Article

References (120)

1. Apkarian A.V., Neugebauer V., Koob G., Edwards S., Levine J.D., Ferrari L., et al. Neural mechanisms of pain and alcohol dependence. Pharmacology, Biochemistry, and Behavior 2013, 112:34-41.
2. Aubry J.M. CRF system and mood disorders. Journal of Chemical Neuroanatomy 2013, 54:20-24.
3. Baiamonte B.A., Valenza M., Roltsch E.A., Whitaker A.M., Baynes B.B., Sabino V., et al. Nicotine dependence produces hyperalgesia: role of corticotropin-releasing factor-1 receptors (CRF1Rs) in the central amygdala (CeA). Neuropharmacology 2014, 77:217-223.
4. Bair M.J., Robinson R.L., Katon W., Kroenke K. Depression and pain comorbidity: a literature review. Archives of Internal Medicine 2003, 163:2433-2445.
5. Bennett D.S. Depression among children with chronic medical problems: a meta-analysis. Journal of Pediatric Psychology 1994, 19:149-169.
6. Bernard J.F., Huang G.F., Besson J.M. Effect of noxious somesthetic stimulation on the activity of neurons of the nucleus centralis of the amygdala. Brain Research 1990, 523:347-350.
7. Blackburn-Munro G., Blackburn-Munro R.E. Chronic pain, chronic stress and depression: coincidence or consequence?. Journal of Neuroendocrinology 2001, 13:1009-1023.
8. Bonci A., Borgland S. Role of orexin/hypocretin and CRF in the formation of drug-dependent synaptic plasticity in the mesolimbic system. Neuropharmacology 2009, 56(Suppl. 1):107-111.
9. Bridges K.W., Goldberg D.P. Somatic presentation of DSM III psychiatric disorders in primary care. Journal of Psychosomatic Research 1985, 29:563-569.
10. Bruchas M.R., Land B.B., Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Research 2010, 1314:44-55.
11. Burke A.R., Miczek K.A. Stress in adolescence and drugs of abuse in rodent models: role of dopamine, CRF, and HPA axis. Psychopharmacology (Berl) 2014, 231:1557-1580.
12. Butelman E.R., Yuferov V., Kreek M.J. κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends in Neurosciences 2012, 35:587-596.
13. Cao H., Gao Y.J., Ren W.H., Li T.T., Duan K.Z., Cui Y.H., et al. Activation of extracellular signal-regulated kinase in the anterior cingulate cortex contributes to the induction and expression of affective pain. The Journal of Neuroscience 2009, 29:3307-3321.
14. Carcoba L.M., Contreras A.E., Cepeda-Benito A., Meagher M.W. Negative affect heightens opiate withdrawal-induced hyperalgesia in heroin dependent individuals. Journal of Addictive Diseases 2011, 30:258-270.
15. Célèrier E., Laulin J.P., Corcuff J.B., Le Moal M., Simonnet G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. The Journal of Neuroscience 2001, 21:4074-4080.
16. Cepeda M.L., Yang Y.M., Price C.C., Shah A. Mental disorders in children and adolescents with sickle cell disease. Southern Medical Journal 1997, 90:284-287.
17. Chartoff E., Sawyer A., Rachlin A., Potter D., Pliakas A., Carlezon W.A. Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology 2012, 62:167-176.
18. Chen L.Y., Huang J.X., Yu L.C. Involvement of ORL1 receptor and ERK kinase in the orphanin FQ-induced nociception in the nucleus accumbens of rats. Regulatory Peptides 2008, 151:43-47.
19. Chopra K., Arora V. An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets. Expert Opinion on Therapeutic Targets 2014, 18:159-176.
20. Cohen A., Treweek J., Edwards S., Leão R.M., Schulteis G., Koob G.F., et al. Extended access to nicotine leads to a CRF1 receptor dependent increase in anxiety-like behavior and hyperalgesia in rats. Addiction Biology 2013, 20:56-68.
21. Currie S.R., Wang J. Chronic back pain and major depression in the general Canadian population. Pain 2004, 107:54-60.
22. Demyttenaere K., Bruffaerts R., Lee S., Posada-Villa J., Kovess V., Angermeyer M.C., et al. Mental disorders among persons with chronic back or neck pain: results from the World Mental Health Surveys. Pain 2007, 129:332-342.
23. Dersh J., Polatin P.B., Gatchel R.J. Chronic pain and psychopathology: research findings and theoretical considerations. Psychosomatic Medicine 2002, 64:773-786.
24. Dina O.A., Khasar S.G., Alessandri-Haber N., Green P.G., Messing R.O., Levine J.D. Alcohol-induced stress in painful alcoholic neuropathy. The European Journal of Neuroscience 2008, 27:83-92.
25. Doan B.D., Wadden N.P. Relationships between depressive symptoms and descriptions of chronic pain. Pain 1989, 36:75-84.
26. American psychiatric association: Diagnostic and statistical manual of mental disorders 2013, DSM-5, American Psychiatric Publishing, Arlington, VA. 5th ed.
27. Dworkin R.H., Gitlin M.J. Clinical aspects of depression in chronic pain patients. The Clinical Journal of Pain 1991, 7:79-94.
28. Edwards S., Baynes B.B., Carmichael C.Y., Zamora-Martinez E.R., Barrus M., Koob G.F., et al. Traumatic stress reactivity promotes excessive alcohol drinking and alters the balance of prefrontal cortex-amygdala activity. Translational Psychiatry 2013, 3:e296.
29. Edwards S., Graham D.L., Whisler K.N., Self D.W. Phosphorylation of GluR1, ERK, and CREB during spontaneous withdrawal from chronic heroin self-administration. Synapse 2009, 63:224-235.
30. Edwards S., Koob G.F. Neurobiology of dysregulated motivational systems in drug addiction. Future Neurology 2010, 5:393-401.
31. Edwards S., Koob G.F. Escalation of drug self-administration as a hallmark of persistent addiction liability. Behavioural Pharmacology 2013, 24:356-362.
32. 1 receptor antagonism. Neuropharmacology 2012, 62:1142-1151.
33. Edwards R.R., Wasan A.D., Michna E., Greenbaum S., Ross E., Jamison R.N. Elevated pain sensitivity in chronic pain patients at risk for opioid misuse. The Journal of Pain 2011, 12:953-963.
34. Egli M., Koob G.F., Edwards S. Alcohol dependence as a chronic pain disorder. Neuroscience and Biobehavioral Reviews 2012, 36:2179-2192.
35. Elman I., Borsook D., Volkow N.D. Pain and suicidality: insights from reward and addiction neuroscience. Progress in Neurobiology 2013, 109:1-27.
36. Ericsson M., Poston W.S., Linder J., Taylor J.E., Haddock C.K., Foreyt J.P. Depression predicts disability in long-term chronic pain patients. Disability and Rehabilitation 2002, 24:334-340.
37. Ewan E.E., Martin T.J. Opioid facilitation of rewarding electrical brain stimulation is suppressed in rats with neuropathic pain. Anesthesiology 2011, 114:624-632.
38. Fields H.L. The doctor's dilemma: opiate analgesics and chronic pain. Neuron 2011, 69:591-594.
39. Fishbain D.A., Cole B., Lewis J., Rosomoff H.L., Rosomoff R.S. What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Medicine 2008, 9:444-459.
40. Fu Y., Han J., Ishola T., Scerbo M., Adwanikar H., Ramsey C., et al. PKA and ERK, but not PKC, in the amygdala contribute to pain-related synaptic plasticity and behavior. Molecular Pain 2008, 4:26.
41. Fuchs P.N., Peng Y.B., Boyette-Davis J.A., Uhelski M.L. The anterior cingulate cortex and pain processing. Frontiers in Integrative Neuroscience 2014, 8:35.
42. George O., Le Moal M., Koob G.F. Allostasis and addiction: role of the dopamine and corticotropin-releasing factor systems. Physiology & Behavior 2012, 106:58-64.
43. Gerrits M.M., Vogelzangs N., van Oppen P., van Marwijk H.W., van der Horst H., Penninx B.W. Impact of pain on the course of depressive and anxiety disorders. Pain 2012, 153:429-436.
44. Goeders N.E. The impact of stress on addiction. European Neuropsychopharmacology 2003, 13:435-441.
45. Haley W.E., Turner J.A., Romano J.M. Depression in chronic pain patients: relation to pain, activity, and sex differences. Pain 1985, 23:337-343.
46. Hasan S.P., Hashmi S., Alhassen M., Lawson W., Castro O. Depression in sickle cell disease. Journal of the National Medical Association 2003, 95:533-537.
47. Hopf F.W., Sparta D.R., Bonci A. Translational models of interactions between stress and alcohol consumption: strengths and limitations. ILAR Journal 2011, 52:239-250.
48. Report from the Committee on Advancing Pain Research, Care, and Education: Relieving pain in America, a blueprint for transforming prevention, care, education and research 2011, Institute of Medicine, The National Academies Press.
49. Ji G., Fu Y., Adwanikar H., Neugebauer V. Non-pain-related CRF1 activation in the amygdala facilitates synaptic transmission and pain responses. Molecular Pain 2013, 9:2.
50. Ji G., Fu Y., Ruppert K.A., Neugebauer V. Pain-related anxiety-like behavior requires CRF1 receptors in the amygdala. Molecular Pain 2007, 3:13.
51. Ji G., Neugebauer V. Differential effects of CRF1 and CRF2 receptor antagonists on pain-related sensitization of neurons in the central nucleus of the amygdala. Journal of Neurophysiology 2007, 97:3893-3904.
52. Johansen J.P., Fields H.L. Glutamatergic activation of anterior cingulate cortex produces an aversive teaching signal. Nature Neuroscience 2004, 7:398-403.
53. Kallupi M., Wee S., Edwards S., Whitfield T.W., Oleata C.S., Luu G., et al. Kappa opioid receptor-mediated dysregulation of gamma-aminobutyric acidergic transmission in the central amygdala in cocaine addiction. Biological Psychiatry 2013, 74:520-528.
54. Kato K., Sullivan P.F., Evengård B., Pedersen N.L. Chronic widespread pain and its comorbidities: a population-based study. Archives of Internal Medicine 2006, 166:1649-1654.
55. King T., Vera-Portocarrero L., Gutierrez T., Vanderah T.W., Dussor G., Lai J., et al. Unmasking the tonic-aversive state in neuropathic pain. Nature Neuroscience 2009, 12:1364-1366.
56. Kirmayer L.J., Robbins J.M., Dworkind M., Yaffe M.J. Somatization and the recognition of depression and anxiety in primary care. The American Journal of Psychiatry 1993, 150:734-741.
57. de Kloet E.R. Lifetime achievement from a brain-adrenal perspective: on the CRF-urocortin-glucocorticoid balance. Journal of Chemical Neuroanatomy 2013, 54:42-49.
58. Knaster P., Karlsson H., Estlander A.M., Kalso E. Psychiatric disorders as assessed with SCID in chronic pain patients: the anxiety disorders precede the onset of pain. General Hospital Psychiatry 2012, 34:46-52.
59. Koob G.F. Brain stress systems in the amygdala and addiction. Brain Research 2009, 1293:61-75.
60. Koob G.F., Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997, 278:52-58.
61. Koob G.F., Le Moal M. Addiction and the brain antireward system. Annual Review of Psychology 2008, 59:29-53.
62. Kroenke K., Bair M.J., Damush T.M., Wu J., Hoke S., Sutherland J., et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. JAMA 2009, 301:2099-2110.
63. Land B.B., Bruchas M.R., Lemos J.C., Xu M., Melief E.J., Chavkin C. The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. The Journal of Neuroscience 2008, 28:407-414.
64. Leshner A.I. Addiction is a brain disease, and it matters. Science 1997, 278:45-47.
65. Levenson J.L., McClish D.K., Dahman B.A., Bovbjerg V.E., de A.Citero V., Penberthy L.T., et al. Depression and anxiety in adults with sickle cell disease: the PiSCES project. Psychosomatic Medicine 2008, 70:192-196.
66. Levenson J.L., McClish D.K., Dahman B.A., Penberthy L.T., Bovbjerg V.E., Aisiku I.P., et al. Alcohol abuse in sickle cell disease: the Pisces Project. The American Journal on Addictions 2007, 16:383-388.
67. Lindsay P.G., Wyckoff M. The depression-pain syndrome and its response to antidepressants. Psychosomatics 1981, 22:571-573. 576-577.
68. Logrip M.L., Zorrilla E.P., Koob G.F. Stress modulation of drug self-administration: implications for addiction comorbidity with post-traumatic stress disorder. Neuropharmacology 2012, 62:552-564.
69. Loyd D.R., Murphy A.Z. The neuroanatomy of sexual dimorphism in opioid analgesia. Experimental Neurology 2014, 259:57-63.
70. Lu L., Koya E., Zhai H., Hope B.T., Shaham Y. Role of ERK in cocaine addiction. Trends in Neurosciences 2006, 29:695-703.
71. Maletic V., Raison C.L. Neurobiology of depression, fibromyalgia and neuropathic pain. Frontiers in Bioscience (Landmark Ed) 2009, 14:5291-5338.
72. Marinelli M., Piazza P.V. Interaction between glucocorticoid hormones, stress and psychostimulant drugs. The European Journal of Neuroscience 2002, 16:387-394.
73. Martin T.J., Kim S.A., Buechler N.L., Porreca F., Eisenach J.C. Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. Anesthesiology 2007, 106:312-322.
74. Mason B.J., Shaham Y., Weiss F., Le A.D. Stress, alcohol craving, and relapse risk: mechanisms and viable treatment targets. Alcohol 2009, 43:541-543.
75. McGinn, M. A., & Edwards, S.. CRF1 receptor signaling at the intersection of pain and opioid addiction. In V. Preedy (Ed.), The neuropathology of drug addictions and substance misuse. (in press).
76. McNally G.P., Akil H. Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. Neuroscience 2002, 112:605-617.
77. McWilliams L.A., Cox B.J., Enns M.W. Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample. Pain 2003, 106:127-133.
78. Minami M. Neuronal mechanisms for pain-induced aversion behavioral studies using a conditioned place aversion test. International Review of Neurobiology 2009, 85:135-144.
79. Mogil J.S., Bailey A.L. Sex and gender differences in pain and analgesia. Progress in Brain Research 2010, 186:141-157.
80. Myrvik M.P., Burks L.M., Hoffman R.G., Dasgupta M., Panepinto J.A. Mental health disorders influence admission rates for pain in children with sickle cell disease. Pediatric Blood & Cancer 2013, 60:1211-1214.
81. Narita M., Kaneko C., Miyoshi K., Nagumo Y., Kuzumaki N., Nakajima M., et al. Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology 2006, 31:739-750.
82. Narita M., Kishimoto Y., Ise Y., Yajima Y., Misawa K., Suzuki T. Direct evidence for the involvement of the mesolimbic kappa-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. Neuropsychopharmacology 2005, 30:111-118.
83. Navratilova E., Porreca F. Reward and motivation in pain and pain relief. Nature Neuroscience 2014, 17:1304-1312.
84. Nestler E.J. Under siege: the brain on opiates. Neuron 1996, 16:897-900.
85. Neugebauer V., Li W., Bird G.C., Han J.S. The amygdala and persistent pain. Neuroscientist 2004, 10:221-234.
86. Park P.E., Schlosburg J.E., Vendruscolo L.F., Schulteis G., Edwards S., Koob G.F. Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia. Addiction Biology 2013, 20:275-284.
87. Ren Z.Y., Shi J., Epstein D.H., Wang J., Lu L. Abnormal pain response in pain-sensitive opiate addicts after prolonged abstinence predicts increased drug craving. Psychopharmacology (Berl) 2009, 204:423-429.
88. Robinson T.E., Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Research. Brain Research Reviews 1993, 18:247-291.
89. Roltsch E.A., Baynes B.B., Mayeux J.P., Whitaker A.M., Baiamonte B.A., Gilpin N.W. Predator odor stress alters corticotropin-releasing factor-1 receptor (CRF1R)-dependent behaviors in rats. Neuropharmacology 2014, 79:83-89.
90. Rouwette T., Klemann K., Gaszner B., Scheffer G.J., Roubos E.W., Scheenen W.J., et al. Differential responses of corticotropin-releasing factor and urocortin 1 to acute pain stress in the rat brain. Neuroscience 2011, 183:15-24.
91. Ruoff G.E. Depression in the patient with chronic pain. The Journal of Family Practice 1996, 43(6 Suppl.):S25-S33. discussion S34.
92. Sanna P.P., Simpson C., Lutjens R., Koob G. ERK regulation in chronic ethanol exposure and withdrawal. Brain Research 2002, 948:186-191.
93. Schlosburg J.E., Whitfield T.W., Park P.E., Crawford E.F., George O., Vendruscolo L.F., et al. Long-term antagonism of κ opioid receptors prevents escalation of and increased motivation for heroin intake. The Journal of Neuroscience 2013, 33:19384-19392.
94. Self D.W. Neural substrates of drug craving and relapse in drug addiction. Annals of Medicine 1998, 30:379-389.
95. Self D.W., Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Annual Review of Neuroscience 1995, 18:463-495.
96. Shurman J., Koob G.F., Gutstein H.B. Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Medicine 2010, 11:1092-1098.
97. Sinha R. The role of stress in addiction relapse. Current Psychiatry Reports 2007, 9:388-395.
98. Steketee J.D., Kalivas P.W. Drug wanting: behavioral sensitization and relapse to drug-seeking behavior. Pharmacological Reviews 2011, 63:348-365.
99. Teh C.F., Zaslavsky A.M., Reynolds C.F., Cleary P.D. Effect of depression treatment on chronic pain outcomes. Psychosomatic Medicine 2010, 72:61-67.
100. Ulrich-Lai Y.M., Xie W., Meij J.T., Dolgas C.M., Yu L., Herman J.P. Limbic and HPA axis function in an animal model of chronic neuropathic pain. Physiology & Behavior 2006, 88:67-76.
101. Van't Veer A., Carlezon W.A. Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology (Berl) 2013, 229:435-452.
102. Volkow N.D., McLellan T.A. Curtailing diversion and abuse of opioid analgesics without jeopardizing pain treatment. JAMA 2011, 305:1346-1347.
103. Walker B.M., Koob G.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 2008, 33:643-652.
104. Wasan A.D., Butler S.F., Budman S.H., Benoit C., Fernandez K., Jamison R.N. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. The Clinical Journal of Pain 2007, 23:307-315.
105. Wasan A.D., Ross E.L., Michna E., Chibnik L., Greenfield S.F., Weiss R.D., et al. Craving of prescription opioids in patients with chronic pain: a longitudinal outcomes trial. The Journal of Pain 2012, 13:146-154.
106. Whitaker A.M., Gilpin N.W., Edwards S. Animal models of post-traumatic stress disorder and recent neurobiological insights. Behavioural Pharmacology 2014, 25:398-409.
107. Widmer R.B., Cadoret R.J. Depression in primary care: changes in pattern of patient visits and complaints during a developing depression. The Journal of Family Practice 1978, 7:293-302.
108. Witkin J.M., Statnick M.A., Rorick-Kehn L.M., Pintar J.E., Ansonoff M., Chen Y., et al. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacology & Therapeutics 2014, 141:283-299.
109. Wolf M.E. The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Progress in Neurobiology 1998, 54:679-720.
110. Woolf C.J. Evidence for a central component of post-injury pain hypersensitivity. Nature 1983, 306:686-688.
111. Woolf C.J. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011, 152(3 Suppl):S2-S15.
112. Wu L.J., Steenland H.W., Kim S.S., Isiegas C., Abel T., Kaang B.K., et al. Enhancement of presynaptic glutamate release and persistent inflammatory pain by increasing neuronal cAMP in the anterior cingulate cortex. Molecular Pain 2008, 4:40.
113. Wu L.J., Toyoda H., Zhao M.G., Lee Y.S., Tang J., Ko S.W., et al. Upregulation of forebrain NMDA NR2B receptors contributes to behavioral sensitization after inflammation. The Journal of Neuroscience 2005, 25:11107-11116.
114. Xie J.Y., Qu C., Patwardhan A., Ossipov M.H., Navratilova E., Becerra L., et al. Activation of mesocorticolimbic reward circuits for assessment of relief of ongoing pain: a potential biomarker of efficacy. Pain 2014, 155:1659-1666.
115. Yalcin I., Barrot M. The anxiodepressive comorbidity in chronic pain. Current Opinion in Anaesthesiology 2014, 27:520-527.
116. Yalcin I., Barthas F., Barrot M. Emotional consequences of neuropathic pain: insight from preclinical studies. Neuroscience and Biobehavioral Reviews 2014, 47:154-164.
117. Yalcin I., Bohren Y., Waltisperger E., Sage-Ciocca D., Yin J.C., Freund-Mercier M.J., et al. A time-dependent history of mood disorders in a murine model of neuropathic pain. Biological Psychiatry 2011, 70:946-953.
118. Zamora-Martinez E.R., Edwards S. Neuronal extracellular signal-regulated kinase (ERK) activity as marker and mediator of alcohol and opioid dependence. Frontiers in Integrative Neuroscience 2014, 8:24.
119. Zhao M.G., Ko S.W., Wu L.J., Toyoda H., Xu H., Quan J., et al. Enhanced presynaptic neurotransmitter release in the anterior cingulate cortex of mice with chronic pain. The Journal of Neuroscience 2006, 26:8923-8930.
120. Zorrilla E.P., Logrip M.L., Koob G.F. Corticotropin releasing factor: a key role in the neurobiology of addiction. Frontiers in Neuroendocrinology 2014, 35:234-244.